Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MCY-M11

Cell therapy (CAR-T) · Kills target cells, directed at mesothelin (MSLN) · developed by MaxCyte

Phase 1 Most advanced trial (none active)
MXCT Developer
1 Registered trials

What is MCY-M11?

MCY-M11 is an autologous peripheral blood mononuclear cell product transfected with anti-mesothelin chimeric antigen receptor mRNA. Given intraperitoneally, it recognizes, binds, phagocytoses and kills cells expressing mesothelin, a cell surface glycoprotein overexpressed in many epithelial-derived cancers. It is studied in peritoneal mesothelioma, fallopian tube adenocarcinoma, ovarian adenocarcinoma and primary peritoneal carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
mesothelin (MSLN) (antigen)
Mechanism
Kills target cells, directed at mesothelin (MSLN)
Pathways
cytotoxic T-lymphocyte response, phagocytosis
Therapy area
Oncology
Developer
MaxCyte, Inc. (MXCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
ER09HM7LIR

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03608618 Phase 1 Peritoneal Mesothelioma Terminated MXCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adenocarcinoma of the OvaryFallopian Tube AdenocarcinomaPeritoneal MesotheliomaPrimary Peritoneal Carcinoma

Other drugs acting on MSLN

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MXCT page.

Follow MXCT, the company behind MCY-M11

See MXCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MXCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.